R&D Trends

Targacept, Catalyst Biosciences ink merger

Monday, March 9, 2015 12:20 PM

Targacept, a biopharma company based in Winston-Salem, N.C., and Catalyst Biosciences, a privately held biopharma company based in South San Francisco, Calif., have agreed to merge. The combined entity, to be named Catalyst Biosciences, is expected to create a financially strong company to harness the catalytic power of engineered human proteases to develop next-generation biopharmaceuticals with improved efficacy and therapeutic index to treat major diseases.

More... »


Biomarkers Across Neurodegenerative Diseases launches $2M funding cycle

Monday, March 9, 2015 12:15 PM

Biomarkers Across Neurodegenerative Diseases (BAND) is launching a new funding cycle of nearly $2 million for projects investigating the overlap in the biology and clinical symptoms of Alzheimer's, Parkinson's, frontotemporal dementia (FTD) and other brain-deteriorating diseases.

More... »


NIH-led effort launches Big Data portal for Alzheimer’s drug discovery

Friday, March 6, 2015 12:16 PM

A NIH-led public-private partnership to transform and accelerate drug development has launched a new Alzheimer’s Big Data portal—including delivery of the first wave of data—for use by the research community. The new data sharing and analysis resource is part of the Accelerating Medicines Partnership (AMP), an unprecedented venture bringing together NIH, FDA, industry and academic scientists from a variety of disciplines to translate knowledge faster and more successfully into new therapies.

More... »

The Bill & Melinda Gates Foundation, CureVac collaborate

Friday, March 6, 2015 12:11 PM

The Bill & Melinda Gates Foundation has made a commitment to invest $52 million in CureVac, a Germany-based, clinical-stage biopharmaceutical company specializing in mRNA-based vaccine technologies.

More... »

Mayo Clinic, Gentag to develop wireless sensors for treatment of obesity and diabetes

Thursday, March 5, 2015 12:35 PM

Mayo Clinic, a nonprofit organization based in Rochester, Minn., and Gentag, a wearable biosensor company based in Washington, D.C., have reached an agreement to develop the next generation of wearable biosensors designed to fight obesity and diabetes.

More... »

Eisai, Merck collaborate on combination regimens for cancer

Thursday, March 5, 2015 12:29 PM

Eisai and Merck, through a subsidiary, have formed a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Merck’s anti-PD-1 therapy, pembrolizumab (marketed in the U.S. under the brand name Keytruda), in combination with Eisai oncology compounds lenvatinib mesylate (a multi-targeting RTK inhibitor marketed in the U.S. under the brand name Lenvima, lenvatinib) and eribulin mesylate (a microtubule dynamics inhibitor marketed in nearly 60 countries including Japan, the U.S. and Europe under the brand name Halaven, eribulin) in multiple clinical trials.

More... »

Denovo Biopharma licenses late-stage neuroscience drug from Eli Lilly

Wednesday, March 4, 2015 01:15 PM

Denovo Biopharma, a privately held biotechnology company based in San Diego, has exclusively licensed Pomaglumetad Methionil (mGlu2/3 receptor agonist), a late-stage neuroscience drug, from Eli Lilly. Denovo gains all rights to develop, manufacture and commercialize pomaglumetad globally, including transfer of all intellectual property and other rights, data and information. Lilly has an option to re-acquire pomaglumetad upon a successful clinical trial, for predetermined undisclosed financial terms.

More... »

Kite Pharma expands R&D collaboration with National Cancer Institute

Wednesday, March 4, 2015 01:11 PM

Kite Pharma, a clinical stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer based in Santa Monica, Calif., has amended its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).

More... »

CCFA, University of Pennsylvania, Nestlé collaborate on IBD study

Wednesday, March 4, 2015 01:09 PM

The Crohn's & Colitis Foundation of America (CCFA) has entered into a research partnership with the Perelman School of Medicine at the University of Pennsylvania and Nestlé Health Science to study the effects of diet on gut bacteria. The study is part of a major CCFA effort to develop new treatments targeting the gut microbiome—the "ecosystem" of microbes populating the intestines—linked to the development of inflammatory bowel diseases (IBD).

More... »

Bristol-Myers Squibb, Bavarian Nordic ink agreement for PROSTVAC

Wednesday, March 4, 2015 01:06 PM

Bristol-Myers Squibb has signed an exclusive option to license and commercialize PROSTVAC, Bavarian Nordic's investigational phase III prostate-specific antigen (PSA)-targeting cancer immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

More... »

CenterWatch
CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs